Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial
Diabetes, Obesity and Metabolism Oct 25, 2019
Tack CJ, Jacob S, Desouza C, et al. - In this post hoc analysis of the LEADER trial including 9,340 individuals, researchers presented long-term safety and effectiveness data for glucagon-like peptide-1 receptor agonist (GLP-1RA) and insulin combination therapy. Participants in the study were randomized 1:1 to liraglutide (up to 1.8 mg, as tolerated) or placebo, plus standard of care treatment, and followed for 3.5 years to 5 years. Investigators found that adding liraglutide to insulin treatment for T2D patients at high cardiovascular (CV) risk improved glycemic control, decreased body weight, and insulin need for at least 36 months and maintained CV safety without increasing the risk of severe hypoglycemia. Such outcomes favor combined therapy with liraglutide and insulin.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries